Vaporizando.com
Vaporizadores => Área Médica - Uso terapéutico => Mensaje iniciado por: 9delta en 28 Agosto, 2014, 20:30:15
-
El cannabis vaporizado es seguro y eficaz en el tratamiento del dolor neuropático
Ocho pacientes que sufrían dolor neuropático crónico lograron una reducción significativa de la intensidad del mismo después de la inhalación de cannabis con un vaporizador. Este es el resultado de un estudio abierto realizado por investigadores israelíes y publicado en el Journal of Pain and Palliative Care Pharmacotherapy. El objetivo del mismo era averiguar la farmacocinética, seguridad, tolerabilidad, eficacia y facilidad de uso del Syqe, un nuevo inhalador portátil térmico para cannabis. Los pacientes se encontraban en un régimen analgésico estable que incluía el cannabis medicinal. Se les administró cannabis a una dosis de 15 mg de THC.
La máxima concentración plasmática de THC fue de 38 ng/ml, que se logró de media a los 3 minutos. La reducción media en la intensidad del dolor fue del 45% y se observó 20 minutos después de la inhalación, volviendo a la línea basal dentro de los 90 minutos siguientes. Respecto a la tolerabilidad, el único evento adverso fue el aturdimiento, con una duración de 15-30 minutos y que no requiso intervención alguna.
http://www.cannabis-med.org/spanish/bulletin/ww_es_db_cannabis_artikel.php?id=358#1 (http://www.cannabis-med.org/spanish/bulletin/ww_es_db_cannabis_artikel.php?id=358#1)
Este es el artículo que han publicado tras el estudio:
The Pharmacokinetics, Efficacy, Safety, and Ease of Use of a Novel Portable Metered-Dose Cannabis Inhaler in Patients With Chronic Neuropathic Pain: A Phase 1a Study.
Eisenberg E (http://www.ncbi.nlm.nih.gov/pubmed?term=Eisenberg%20E%5BAuthor%5D&cauthor=true&cauthor_uid=25118789), Ogintz M (http://www.ncbi.nlm.nih.gov/pubmed?term=Ogintz%20M%5BAuthor%5D&cauthor=true&cauthor_uid=25118789), Almog S (http://www.ncbi.nlm.nih.gov/pubmed?term=Almog%20S%5BAuthor%5D&cauthor=true&cauthor_uid=25118789).
ABSTRACT
Chronic neuropathic pain is often refractory to standard pharmacological treatments. Although growing evidence supports the use of inhaled cannabis for neuropathic pain, the lack of standard inhaled dosing plays a major obstacle in cannabis becoming a "main stream" pharmacological treatment for neuropathic pain. The objective of this study was to explore the pharmacokinetics, safety, tolerability, efficacy, and ease of use of a novel portable thermal-metered-dose inhaler (tMDI) for cannabis in a cohort of eight patients suffering from chronic neuropathic pain and on a stable analgesic regimen including medicinal cannabis. In a single-dose, open-label study, patients inhaled a single 15.1 ± 0.1 mg dose of cannabis using the Syqe Inhaler device. Blood samples for Δ9-tetrahydrocannabinol (THC) and 11-hydroxy-Δ9-THC were taken at baseline and up to 120 minutes. Pain intensity (0-10 VAS), adverse events, and satisfaction score were monitored following the inhalation. A uniform pharmacokinetic profile was exhibited across all participants (Δ9-THC plasma Cmax ± SD was 38 ± 10 ng/mL, Tmax ± SD was 3 ± 1 minutes, AUC0→infinity ± SD was 607 ± 200 ng·min/mL). Higher plasma Cmax increase per mg Δ9-THC administered (12.3 ng/mL/mg THC) and lower interindividual variability of Cmax (25.3%), compared with reported alternative modes of THC delivery, were measured. A significant 45% reduction in pain intensity was noted 20 minutes post inhalation (P = .001), turning back to baseline within 90 minutes. Tolerable, lightheadedness, lasting 15-30 minutes and requiring no intervention, was the only reported adverse event. This trial suggests the potential use of the Syqe Inhaler device as a smokeless delivery system of medicinal cannabis, producing a Δ9-THC pharmacokinetic profile with low interindividual variation of Cmax, achieving pharmaceutical standards for inhaled drugs.
http://www.ncbi.nlm.nih.gov/pubmed/25118789 (http://www.ncbi.nlm.nih.gov/pubmed/25118789)
Dentro de unos meses espero conseguirlo.
-
:thks: